due to financial problems

Hemodialysis patients with low bone density (total hip T-score <-2.5) will be assigned to receive teriparatide (those with histologic confirmation of adynamic bone disease) or ibandronate (subjects with increased osteoclast number on bone biopsy).

Follow-up period: one year. A second bone biopsy at the end of the study.

Inclusion Criteria:

• Bone mineral density (T-score<-2.5)
• Adynamic bone disease for the teriparatide group
• Increased osteoclast number on bone biopsy (high turnover) for the ibandronate group
• Calcium greater than 8.1 mg/dl

Exclusion Criteria:

• Suspected carcinoma
• Unstable clinical setting